Drugs / Elobixibat
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 4 met primary | ||||||
| Phase 2 | NCT04235205 | Jan 2020 → Jul 2021 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Yokohama City University | Completed | No outcome recorded |
| Phase 2 | NCT04006145 | Jun 2019 → Jun 2020 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Albireo | Completed | Met primary |
| Phase 2 | NCT02392546 | Apr 2015 → Apr 2016 | constipation disorder | Ferring Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01069783 | Feb → Sep 2010 | hyperlipidemia | Albireo | Completed | Met primary |
| Phase 2 | NCT01038687 | Jan 2010 → Jan 2011 | constipation disorder | Michael Camilleri, MD | Completed | Met primary |
| Phase 2 | NCT01007123 | Nov 2009 → Oct 2010 | constipation disorder | Albireo | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT01895543 | Sep 2013 → May 2015 | constipation disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01827592 | Apr 2013 → Mar 2014 | constipation disorder | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01833065 | Apr 2013 → Mar 2014 | constipation disorder | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05703464 | Feb → Mar 2023 | constipation disorder | International University of Health and Welfare | Terminated | No outcome recorded |
| Phase 4 | NCT05165199 | Mar → Sep 2022 | constipation disorder | Yokohama City University | Unknown | No outcome recorded |
| Phase 4 | NCT04784780 | Aug 2021 → Jun 2023 | constipation disorder | Yokohama City University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06436833 | May → Nov 2024 | — | Department of Medical Services Ministry of Public Health of Thailand | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05895877 Comparator | Dec 2021 → Sep 2023 | constipation disorder | Synmosa Biopharma Corp. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
All press releases naming this drug 8 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elobixibat | “Active ingredient:
Elobixibat 5mg/tab
Dosage and Frequency:
Once daily before breakfast. The starting dose is total 10 mg of Goofice® (2 tablets).” NCT05895877 ↗12“Thirty-six dyslipidemic patients, 21 females, mean age 63 years, were randomized to 2.5 mg or 5 mg elobixibat or placebo once daily for four weeks.” PMID 26197999 ↗ Jul 2015 “Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation” NCT01007123 ↗ |
| Known as | A3309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01038687 ↗ |
| Known as | AZD-7806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039515 ↗ |
| Known as | EXB | “Elobixibat (EXB) specifically inhibits the ileal bile acid transporter/apical sodium-dependent bile acid transporter, which is a transporter involved in the reabsorption of...” PMID 35812817 ↗ Jun 20222“Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter.” PMID 32907904 ↗ Sep 2020 “elobixibat (EXB) versus placebo” PMID 35636802 ↗ May 2022 |
| Known as | Goofice | “Active ingredient: Elobixibat 5mg/tab Dosage and Frequency: Once daily before breakfast. The starting dose is total 10 mg of Goofice® (2 tablets).” NCT05895877 ↗ |
| Action | Inhibit | “A3309 is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor.” PMID 21606974 ↗ May 20111“Ileal bile acid transporter inhibitor” CHEMBL3039515 ↗ |
| Modality | Small molecule | “The objective of this study was to examine gastrointestinal (GI) transit effects of A3309, a small molecule inhibitor of the ileal BA transporter, in patients with functional...” PMID 21876564 ↗ Aug 2011 |
| Route | Oral | “In a double-blind, placebo-controlled study of 36 female FC patients randomized to placebo, 15 mg A3309, or 20 mg A3309 administered orally once daily for 14 consecutive days,...” PMID 21876564 ↗ Aug 2011 |
| Target | SLC10A2 | “Ileal bile acid transporter inhibitor” CHEMBL3039515 ↗ |